Erdafitinib (Erdafitinib) effects and efficacy

Erdafitinib(Erdafitinib)is an anti-tumor drug. Erdafitinib treatment has susceptibility to FGFR-2 or FGFR-3genomic aberrations(Local advanced or metastatic urothelial carcinoma, such as gene mutations, gene fusions), during or after ≥1 prior platinum-containing therapy, including within 12 months of platinum-containing therapy in the neoadjuvant or adjuvant setting.

The efficacy of erdafitinib was studied in a clinical trial (NCT02365597) that included 87 patients. Adults with locally advanced or metastatic bladder cancer that has FGFR3 or FGFR2 gene alterations that have progressed after chemotherapy. The overall response rate in these adults was 32.2%, with 2.3% having a complete response and nearly 30% having a partial response. Responses took a median of about five and a half months and trials were conducted in Asia, Europe and the United States.

ErdafitinibCommon side effects include increased phosphate levels, mouth sores, feeling tired, changes in kidney function, diarrhea, dry mouth, nail separation from the bed or poor nail formation, changes in liver function, low salt(sodium< span>) levels, decreased appetite, changes in taste, low red blood cells(anemia), dry skin, dry eyes, and hair loss. Other side effects include redness, swelling, peeling or tenderness of the hands or feet(Hand-foot syndrome), constipation, stomach pain, nausea and muscle pain. The dosage of generic drugs is the same as that of original drugs, but the price is favorable. Each box of generic drugs is about 2more than more than . If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.